Author(s): Lapchak PA
Importance of the field:Curcumin has been investigated in preclinical and translational stroke models because of its pleiotropic 'neuroprotective' activities. Since curcumin has poor blood-brain barrier (BBB) penetration following acute administration, creative medicinal chemistry has been used to modify the parent curcumin molecule, resulting in second generation curcuminoids, which have enhanced BBB penetration, improved pharmacokinetics and interact with multiple viable targets to treat stroke.
Areas covered in this review:This review covers epidemiological, preclinical and translational data published between 2002 and 2010.
What the reader will gain:There are two main goals: First, epidemiological data comparing the incidence of stroke in North America to that of India, a country where curcumin is a main-stay of the diet is presented. Second, the pharmacological characteristics of curcuminoids are detailed to determine if they should be further studied in translational stroke models for safety and efficacy prior to initiating clinical trials.
Take home message:Curcumin and curcuminoids are neuroprotective in a variety of preclinical stroke models. The novel multi-target curcuminoid, CNB-001, has a superior safety and pharmacokinetic profile and should be further developed as an acute monotherapy or to be used in conjunction with thrombolytics for acute ischemic stroke.
Referred From: https://www.ncbi.nlm.nih.gov/pubmed/21158690
Author(s): Fang MC, Cutler DM, Rosen AB
Author(s): Reeves MJ, Arora S, Broderick JP, Frankel M, Heinrich JP, et al.
Author(s): Schwamm LH, Ali SF, Reeves MJ, Smith EE, Saver JL, et al.
Author(s): Lapchak PA
Author(s): Schellinger PD, Fiebach JB, Mohr A, Ringleb PA, Jansen O, et al.
Author(s): Schellinger PD, Fiebach JB, Mohr A, Ringleb PA, Jansen O, et al.
Author(s): Verstraete M
Author(s): [No authors listed]
Author(s): Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, et al.
Author(s): Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, et al.
Author(s): Savitz SI, Lew R, Bluhmki E, Hacke W, Fisher M
Author(s): Schubert D, Piasecki D
Author(s): Tan S, Schubert D, Maher P
Author(s): Liu Y, Dargusch R, Maher P, Schubert D
Author(s): Lapchak PA, McKim JM Jr
Author(s): Valera E, Dargusch R, Maher PA, Schubert D
Author(s): Jayaraj RL, Tamilselvam K, Manivasagam T, Elangovan N
Author(s): Lapchak PA, Schubert DR, Maher PA
Author(s): Panzhinskiy E, Hua Y, Lapchak PA, Topchiy E, Lehmann TE, et al.
Author(s): Narumoto O, Matsuo Y, Sakaguchi M, Shoji S, Yamashita N, et al.
Author(s): Elgebaly MM, Ogbi S, Li W, Mezzetti EM, Prakash R, et al.
Author(s): Moskowitz MA, Lo EH, Iadecola C
Author(s): Lapchak PA
Author(s): Liu Y, Dargusch R, Maher P, Schubert D
Author(s): Chandler WL, Alessi MC, Aillaud MF, Henderson P, Vague P, et al.
Author(s): Chandler WL, Trimble SL, Loo SC, Mornin D
Author(s): Liot G, Benchenane K, Léveillé F, López-Atalaya JP, Fernández-Monreal M, et al.
Author(s): Fisher M1; Stroke Therapy Academic Industry Roundtable
Author(s): Stroke Therapy Academic Industry Roundtable (STAIR)1
Author(s): Spengos K, Behrens S, Daffertshofer M, Dempfle CE, Hennerici M
Author(s): Schulz KF, Altman DG, Moher D; CONSORT Group
Author(s): Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, et al.
Author(s): Lapchak PA
Author(s): Ebinger M, Winter B , Wendt M, Weber JE, Waldschmidt C, et al.
